Tech Company Financing Transactions
Dioseve Funding Round
Dioseve, based in Tokyo, secured $7 million from Archetype Ventures, D4V and DG Daiwa Ventures.
Transaction Overview
Company Name
Announced On
6/17/2026
Transaction Type
Venture Equity
Amount
$7,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance the development and clinical translation of ReproNest, building out manufacturing and quality management infrastructure, and expanding regulatory and business development activities.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
2-3-11 Nihonbashihoncho, Chuo-ku
Tokyo, 103-0023
Japan
Tokyo, 103-0023
Japan
Phone
Undisclosed
Website
Email Address
Overview
Our revolutionary technology, DIO (Directly Induced Oocyte), is capable of producing an extremely large yield of fertilizable egg cells at a minimal cost in a fraction of the time. We aim to create state-of-the-art solutions to a myriad of problems surrounding pregnancy, including infertility as a result of age and hereditary disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kazuma Kishida
Chief Scientific Officer
Nobuhiko Hamazaki
Browse more venture capital transactions:
Prev: 6/16/2026: Atom Computing venture capital transaction
Next: 6/17/2026: Twenty Technologies venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs